Skip to main content
. 2017 Apr 12;8(29):47250–47268. doi: 10.18632/oncotarget.16872

Figure 8. The model for the role of GBK in inhibiting breast tumorigenesis.

Figure 8

GBK selectively inhibits the G1-S-phase transition in breast cancer cells by induction of the CDK inhibitor p27 expression as well as inhibition of cyclin E/CDK2 complex activities. In turn, MCM proteins are markedly downregulated in MCF-7 cells treated with GBK. GBK also kills breast cancer cells by inducing cell apoptosis through JNK signaling.